Terry Kohler - 15 Mar 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: VRCA
Reported as of: 15 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Mar 2024, 16:31:05 UTC
Prior SEC filing: 16 Nov 2023
Next SEC filing: 28 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark Ballantyne, Attorney-in-Fact

Key filing fact

Terry Kohler filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 19 Mar 2024.

Key facts

This page summarizes Terry Kohler's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Mar 2024, 16:31.

Change

Previous filing in this sequence was filed on 16 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRCA transaction

Common Stock

Award

Transaction value: $0
Shares: +40,000
Change %: +116%
Price: $0.000000
Shares after: 74,416
Date: 15 Mar 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRCA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 15 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $4.80
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date.

Footnote F2

25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.